Hyalex
Lexington, US · Founded 2016 · Delaware corporation · 24 employees on LinkedIn · 4 known investors
Find your way into Hyalex
962 people in our graph share verified history with the Hyalex team — schools, employers, funds. One of them is your warm intro.
Drew Burdonunlockedknows Carl Vause · together at Smith+Nephew (overlapped)
×5knows the team · via World Economic Forum
×2knows the team · via US Navy
knows the team · via 3M
×3knows the team · via MIT Sloan School of Management
HYALEX Orthopaedics develops a synthetic cartilage platform for joint repair in orthopaedic surgery. The company aims to restore damaged joints for patients undergoing surgical intervention.
Founders & leadership
CV
Carl VauseinChief Executive Officer, President, DirectorCarl Vause is a former CEO of Soft Robotics Inc. and has held senior roles at 3M, Nestlé, and Smith & Nephew. He holds a BSEE from Virginia Military Institute and an MBA from London Business School, and served as a Naval Flight Officer in the United States Navy.
MS
Mira SahneyinPresident, CEO and Board Member2017–2021Mira Sahney has held executive and CEO roles at life sciences companies spanning aerospace, automotive, and industrial equipment sectors, with P&L responsibility across startups and established organizations. Her background includes leadership positions at Medtronic and Smith + Nephew, where she drove business turnarounds and growth initiatives, along with earlier success scaling healthcare businesses.
DM
David MyungNamed on SEC filing
Board
MH
Michael HawkinsBoard director
WH
WH
VK
V. Kadir KadhiresanBoard director
AG
Investors · 4
Reported raises · per SEC filings
Form D private placements$45.5M disclosed across 2 rounds · 2017–2024
▶$14.9MraisedOct 2024 · 7 investors · Other Health CareRule 506(b)
▶$14.9MraisedOct 2024 · 7 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Michael HawkinsDirector
- Adam GridleyDirector
- Wende HuttonDirector
- David MyungDirector
- William HarringtonDirector
- Brad ValeDirector
- Carl VauseExecutive Officer, Director
- Offering amount
- $18.1M
- Amount sold
- $14.9M
- First sale
- Sep 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$30.6MraisedJul 2021 · 22 investors · Other Health CareRule 506(b)
▶$30.6MraisedJul 2021 · 22 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- V. Kadir KadhiresanDirector
- Mira SahneyExecutive Officer, Director
- Brad ValeDirector
- Michael HawkinsDirector
- Wende HuttonDirector
- David MyungDirector
- William HarringtonDirector
- Offering amount
- $34.9M
- Amount sold
- $30.6M
- First sale
- May 2017
- Incorporated
- Corporation, Delaware, 2016
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 4
by search overlap
Orthofix (NASDAQ:OFIX)5 shared keywordsOrthofix develops medical devices and surgical solutions for orthopedic procedures, with a focus on spine surgery and limb reconstruction. The company serves physicians and patients globally and emphasizes product quality, safety, and environmental responsibility in its operations.
Bioworld5 shared keywordsBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
Read the Press Release5 shared keywordsStryker is a medical technology company that develops and manufactures products across areas such as orthopaedics, surgical equipment, neurotechnology, and spine care for hospitals and healthcare providers. It operates globally across the Americas, Europe, Asia-Pacific, and the Middle East.
Organogenesis4 shared keywordsOrganogenesis is a regenerative medicine company that develops and commercializes products for the advanced wound care and surgical biologics markets, supplying clinicians and their patients. Its product portfolio includes tissue-based therapies such as Apligraf for wound care.
Companies competing with Hyalex for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does Hyalex do?
- HYALEX Orthopaedics develops a synthetic cartilage platform for joint repair in orthopaedic surgery. The company aims to restore damaged joints for patients undergoing surgical intervention.
- Who are Hyalex's investors?
- Hyalex's investors include Canaan Partners, OUP (Osage University Partners), Treo Ventures, Llc, Johnson & Johnson Innovation – JJDC.
- How much funding has Hyalex raised?
- Hyalex has disclosed $45.5M raised across 2 rounds.
- Where is Hyalex headquartered?
- Hyalex is headquartered in Lexington, US.